| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Respiratory Medicine, the Alfred Hospital and Monash University Medical School, Melbourne and 2 Discipline of Medicine, University of Tasmania Medical School, Hobart, Australia. 3 Lung Biology and Transplant Group, University of Newcastle upon Tyne and the Freeman Hospital, Newcastle upon Tyne, UK
CORRESPONDENCE: E.H. Walters, University of Tasmania Medical School, Hobart, 7001, Tasmania, Australia. Fax: 61 362264894. E-mail: Haydn.Walters@utas.edu.au
Keywords: asthma, bronchoalveolar lavage, interleukin-8, myeloperoxidase, neutrophils, salmeterol
Received: November 27, 2002
Accepted January 23, 2003
This study was supported by the National Health and Medical Research Council, (Canberra, Australia), Alfred Hospital Foundation (Melbourne, Australia), Royal Hobart Hospital Research Foundation (Hobart, Australia) and GlaxoSmithKline (Boronia, Australia).
In-vitro data suggest that long-acting ß2-agonists may have a neutrophil-stabilising effect. A reduction in airway wall eosinophil number following introduction of salmeterol in persistent asthma has previously been described. There is currently interest in the "neutrophil system" in asthma, and thus the aim of the present study was to investigate the effect of salmeterol on interleukin (IL)-8, neutrophils and myeloperoxidase (MPO) in persistent asthma.
In the same 12-week double-blind parallel-group placebo-controlled study as described previously, the effects on bronchoalveolar lavage fluid (BALF) IL-8, neutrophils and MPO of introducing salmeterol (50 µg b.i.d.) or giving additional inhaled corticosteroid (fluticasone 100 µg b.i.d.) in 45 subjects with persistent asthma already on low/moderate doses of inhaled corticosteroids were further investigated.
At baseline, BALF IL-8 but not neutrophil or MPO levels were significantly raised in the asthmatic subjects compared to normal controls. MPO levels correlated strongly with IL-8 levels, and weakly with BALF neutrophil numbers in the asthmatics. Fluticasone treatment resulted in significantly elevated neutrophil numbers, but not MPO or IL-8 levels. In contrast, introducing salmeterol significantly reduced IL-8 and MPO levels, but did not affect BALF neutrophil numbers. Interestingly, salmeterol and fluticasone showed significantly contrasting effects on MPO and neutrophils, and there was a divergent effect on IL-8 levels that almost reached significance.
Excessive interleukin-8 levels may be relevant to asthma pathogenesis, even in the setting of moderate-dose inhaled corticosteroid therapy. Reduction in interleukin-8 production and possibly stabilisation of airway neutrophil numbers may explain the greater clinical benefit of adding a long-acting ß2-agonist rather than merely increasing inhaled corticosteroid doses. Indeed, high-dose inhaled corticosteroid therapy alone may promote airway neutrophilia.
This article has been cited by other articles:
|
|
 |
|
  E H Walters, R Wood-Baker, D E C Reid, and C Ward Innate immune activation in neutrophilic asthma Thorax, January 1, 2008; 63(1): 88 - 89. [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Walters, D. W. Reid, D. P. Johns, and C. Ward Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling Eur. Respir. J., September 1, 2007; 30(3): 574 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mohsenin, M. D. Burdick, J. G. Molina, M. P. Keane, and M. R. Blackburn Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease FASEB J, April 1, 2007; 21(4): 1026 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Chorley, Y. Li, S. Fang, J.-A. Park, and K. B. Adler (R)-Albuterol Elicits Antiinflammatory Effects in Human Airway Epithelial Cells via iNOS Am. J. Respir. Cell Mol. Biol., January 1, 2006; 34(1): 119 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Proskocil and A. D. Fryer {beta}2-Agonist and Anticholinergic Drugs in the Treatment of Lung Disease Proceedings of the ATS, November 1, 2005; 2(4): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maneechotesuwan, S. Essilfie-Quaye, S. Meah, C. Kelly, S. A. Kharitonov, I. M. Adcock, and P. J. Barnes Formoterol Attenuates Neutrophilic Airway Inflammation in Asthma Chest, October 1, 2005; 128(4): 1936 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Basyigit, F. Yildiz, S. K. Ozkara, E. Yildirim, H. Boyaci, and A. Ilgazli The Effect of Clarithromycin on Inflammatory Markers in Chronic Obstructive Pulmonary Disease: Preliminary Data Ann. Pharmacother., September 1, 2004; 38(9): 1400 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barczyk, E. Sozanska, M. Trzaska, and W. Pierzchala Decreased Levels of Myeloperoxidase in Induced Sputum of Patients With COPD After Treatment With Oral Glucocorticoids Chest, August 1, 2004; 126(2): 389 - 393. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
